Key points are not available for this paper at this time.
Linezolid has gained increased use for the treatment of infections caused by multidrug-resistant Gram-positive bacteria in recent years. It can cause rare but potentially life-threatening lactic acidosis. Here, we presented a case report of linezolid-induced lactic acidosis (LILA), along with a systematic review of current literature. The patient was a 55-year-old male who presented with the symptoms of acute cholecystitis. He had been treated for sepsis due to acute cholecystitis with broad-spectrum antibiotics and intravenous fluids as per protocol. Still, his lactate level was getting elevated. After excluding other causes of lactic acidosis, LILA was diagnosed, and linezolid was discontinued. His lactic acid level, as well as his physical condition, improved after that. Studies related to LILA were searched in Medline via PubMed. After screening titles, abstracts, and full texts, data were extracted, tabulated, and presented in this article. The risk of bias was also assessed. We found 78 relevant articles in the primary search, and 26 articles, including 496 patients, were included in the study. From 23 studies of 129 patients, 28 patients (21.7%) died in the setting of LILA. The peak lactate level in which the patient developed LILA was 38.1 mmol/L after four weeks of therapy. The most common health conditions associated with LILA were end-stage renal failure (ESRD), diabetes mellitus (DM), hypertension, chronic obstructive pulmonary disease (COPD), etc. Eighteen studies with a total of 30 patients discontinued it after the development of LILA. Twenty-four patients (80%) out of 30 survived after the discontinuation. We recommend including LILA in the differential diagnoses when treating patients with lactic acidosis since LILA is associated with a relatively elevated mortality rate.
Akter et al. (Thu,) studied this question.